913239-30-2

Upstream product

• 621-84-1 O-benzyl carbamate 
• 222610-50-6 tris-(4-acetamidophenyl)phosphite 
• 695171-91-6 4-(tert-butyloxycarbonylamino)phenylacetaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 
• 104060-23-3 tert-butyl N-[4-(2-hydroxyethyl)phenyl]carbamate 

Downstream Products

• 913239-59-5 di-(4-acetamidophenyl) 1-[(N-benzyloxycarbonyl-O-tert-butyl-D-seryl)-L-alanyl]amino-2-{4-[N,N'-bis(tert-butyloxycarbonyl)guanidino]phenyl}ethanephosphonate 
• 913239-31-3 di-(4-acetamidophenyl) 1-(benzyloxycarbonylamino)-2-{4-[N,N'-bis(tert-butyloxycarbonyl)guanidino]phenyl}ethanephosphonate 
• 934622-42-1 di(4-acetamidophenyl) 1-amino-2-{4-[N,N'-bis(tert-butyloxycarbonyl)guanidino]phenyl}ethanephosphonate 
• 934622-38-5 benzyl 1-(bis(4-acetamidophenoxy)phosphoryl)-2-(4-amino-phenyl)ethylcarbamate 

Relevant academic research and scientific papers

One-pot synthesis of α-aminophosphonates by yttrium-catalyzed Birum-Oleksyszyn reaction

For the first time, yttrium triflate was used as an efficient green catalyst for the synthesis of α-aminophosphonates through a one-pot three-component Birum-Oleksyszyn reaction. Under the action of this Lewis acid, enhancement of the yield and reaction c

Novel Urokinase Inhibitors

The present invention relates to novel compounds with inhibitory activity towards urokinase plasminogen activator (uPA); to methods for preparation of said uPA inhibitor compounds; to pharmaceutical compositions comprising said uPA inhibitor compounds; to

NOVEL UROKINASE INHIBITORS

The present invention relates to novel compounds with inhibitory activity towards urokinase plasminogen activator (uPA); to methods for preparation of said uPA inhibitor compounds; to pharmaceutical compositions comprising said uPA inhibitor compounds; to

Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: Optimization of the P4 position

This paper describes the structure-activity relationship in a series of tripeptidyl diphenyl phosphonate irreversible urokinase plasminogen activator (uPA) inhibitors, originally derived from an arginyltripeptide. uPA is considered an interesting target i